Prosecution Insights
Last updated: April 19, 2026

Examiner: REN, HONG

Tech Center 1600 • Art Units: 1647

This examiner grants 0% of resolved cases

Performance Statistics

%
Allow Rate
-60.0% vs TC avg
5
Total Applications
Interview Lift
1175
Avg Prosecution Days
Based on 0 resolved cases, 2023–2026

Rejection Statute Breakdown

0%
§101 Eligibility
21.7%
§102 Novelty
26.1%
§103 Obviousness
21.7%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18142196 Anti-Interleukin-4 Receptor (IL-4R) Antibody Formulations Non-Final OA Regeneron Pharmaceuticals, Inc.
18352081 METHODS AND COMPOSITIONS FOR PRODUCING TARGETED MICROBUBBLES Non-Final OA The Board of Trustees of the Leland Stanford Junior University
18303407 DNA THERAPEUTIC ENCODING AN ANTIBODY OR ANTIGEN BINDING FRAGMENT Non-Final OA Entos Pharmaceuticals, Inc.
18327402 CLAUDIN 18.2 ANTIBODIES, METHODS OF MAKING THE SAME, AND USES THEREOF Non-Final OA Integral Molecular, Inc.

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month